The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TACE plus sorafenib for the treatment of hepatocellular carcinoma: Final results of the multicenter SOCRATES trial.
A. Erhardt
Consultant or Advisory Role - Bayer
F. T. Kolligs
No relevant relationships to disclose
M. M. Dollinger
No relevant relationships to disclose
E. Schott
No relevant relationships to disclose
H. Wege
No relevant relationships to disclose
M. Bitzer
No relevant relationships to disclose
C. Gog
No relevant relationships to disclose
J. Raedle
No relevant relationships to disclose
M. Schuchmann
No relevant relationships to disclose
C. Walter
No relevant relationships to disclose
D. Blondin
No relevant relationships to disclose
C. Ohmann
No relevant relationships to disclose
D. Haeussinger
No relevant relationships to disclose